Oct 25 2024 This Week in Cardiology

Oct 25 2024 This Week in Cardiology

Up next

Feb 06 2026 This Week in Cardiology

Problems with the PREVENT score, a breakthrough in lipid-lowering therapy, a surprising benefit in stroke care, and more thoughts on statins and preventive care of heart disease are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healt ...  Show more

Jan 30 2026 This Week in Cardiology

Listener feedback, huge news in the rapidly expanding world of PFA AF Ablation, obesity, and a beautiful trial studying an AI-enhanced diagnostic tool in the office are the topics discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare prof ...  Show more

Recommended Episodes

Episode 072: Introduction to Diffuse Large B-Cell Lymphoma (DLBCL)
The Fellow on Call: The Heme/Onc Podcast

This week, we kick off a new series focusing on diffuse large B-cell lymphoma. In this first episode, we discuss the basics that everyone needs to understand before diving into the management of this disease.

<p class="" style="white- ...  Show more

Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)
The Fellow on Call: The Heme/Onc Podcast

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ...

  Show more

Episode 116: AML Series, Pt. 2 - MDS/AML Diagnosis and Risk Stratification
The Fellow on Call: The Heme/Onc Podcast

In this week’s episode, we discuss the diagnostic criteria and risk stratification for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), building on our discussion from last week. Also, if you have not done so, please do check out our hemepath series to ensure y ...

  Show more

Episode 137: Follicular Lymphoma Series, Pt 2. - Front-line Management
The Fellow on Call: The Heme/Onc Podcast

This week, we continue our conversation on follicular lymphoma, this time focusing on front line therapy. We discuss how we approach localized and diffuse disease and the data behind why we do what we do. </ ...

  Show more